JP2014503198A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503198A5
JP2014503198A5 JP2013541026A JP2013541026A JP2014503198A5 JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5 JP 2013541026 A JP2013541026 A JP 2013541026A JP 2013541026 A JP2013541026 A JP 2013541026A JP 2014503198 A5 JP2014503198 A5 JP 2014503198A5
Authority
JP
Japan
Prior art keywords
bip
seq
heavy chain
human immunoglobulin
immunoglobulin heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013541026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503198A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061862 external-priority patent/WO2012071422A2/en
Publication of JP2014503198A publication Critical patent/JP2014503198A/ja
Publication of JP2014503198A5 publication Critical patent/JP2014503198A5/ja
Withdrawn legal-status Critical Current

Links

JP2013541026A 2010-11-22 2011-11-22 組換え酵素および他のタンパク質のタンパク質発現および分泌を改善する新規シグナル配列 Withdrawn JP2014503198A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
US61/415,926 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Publications (2)

Publication Number Publication Date
JP2014503198A JP2014503198A (ja) 2014-02-13
JP2014503198A5 true JP2014503198A5 (enExample) 2015-01-22

Family

ID=46146394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541026A Withdrawn JP2014503198A (ja) 2010-11-22 2011-11-22 組換え酵素および他のタンパク質のタンパク質発現および分泌を改善する新規シグナル配列

Country Status (19)

Country Link
US (1) US9279007B2 (enExample)
EP (2) EP2643468B1 (enExample)
JP (1) JP2014503198A (enExample)
KR (2) KR20190060888A (enExample)
CN (1) CN103328649B (enExample)
BR (1) BR112013012671B1 (enExample)
CA (1) CA2818689C (enExample)
CY (1) CY1121049T1 (enExample)
DK (2) DK2643468T3 (enExample)
ES (2) ES2687415T3 (enExample)
HR (1) HRP20181315T1 (enExample)
HU (1) HUE039070T2 (enExample)
LT (1) LT2643468T (enExample)
PL (1) PL2643468T3 (enExample)
PT (1) PT2643468T (enExample)
RS (1) RS57601B1 (enExample)
SI (1) SI2643468T1 (enExample)
SM (1) SMT201800466T1 (enExample)
WO (1) WO2012071422A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2763526T3 (es) 2014-07-03 2020-05-29 Hoffmann La Roche Sistemas de expresión de polipéptidos
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
KR20200090889A (ko) 2017-11-30 2020-07-29 아미쿠스 세라퓨틱스, 인코포레이티드 Cdkl5 발현 변이체 및 cdkl5 융합 단백질
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
JP7749322B2 (ja) 2018-04-30 2025-10-06 アミカス セラピューティックス インコーポレイテッド 遺伝子治療構築物及び使用方法
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EA202190999A1 (ru) 2018-10-10 2021-10-15 Амикус Терапьютикс, Инк. Композиции на основе полипептидов, стабилизированных с помощью дисульфидной связи, и способы применения
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
SG11202105267VA (en) * 2018-12-19 2021-07-29 Versameb Ag Rna encoding a protein
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
CA3134485A1 (en) * 2019-04-30 2020-11-05 James M. Wilson Compositions useful for treatment of pompe disease
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス, インコーポレイテッド Ca2の組成物および調整可能な制御方法
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CA3156506A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
MX2023006445A (es) 2020-12-01 2023-08-10 Univ Pennsylvania Composiciones y usos de estas para el tratamiento del síndrome de angelman.
WO2023086939A1 (en) 2021-11-12 2023-05-19 Amicus Therapeutics, Inc. Compositions and methods for treating mucopolysaccharidosis iiia
WO2025264978A2 (en) 2024-06-20 2025-12-26 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a proteins and gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352286C (en) * 1998-11-24 2011-07-12 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kd heat shock protein
US7279564B2 (en) * 2003-11-06 2007-10-09 Genencor International, Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Similar Documents

Publication Publication Date Title
WO2012071422A3 (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
JP2005120106A5 (enExample)
JP2020500015A5 (enExample)
JP2003524587A5 (enExample)
JP2023518596A5 (enExample)
JP2019521643A5 (enExample)
DK2190863T3 (en) New albumin binding compositions, methods and uses
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
JP2018033454A5 (enExample)
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
Gallizia et al. Production of a soluble and functional recombinant streptavidin inescherichia coli
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
CA2636075A1 (en) Chimaeric fusion protein with superior chaperone and folding activities
JP2016508143A5 (enExample)
RU2016105586A (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину и эффекторный компонент, и способы ее получения
JP2008509682A5 (enExample)
CN118420750A (zh) 抗猴痘病毒a35r蛋白的单克隆抗体8d7或其抗体片段
JP2017526625A5 (enExample)
CN102101889A (zh) 一种非洲猪瘟病毒vp73基因的原核表达蛋白及其制备方法
ES2299582T3 (es) Vectores de expresion que codifican peptidos señal de bacteriofagos.
JP6199054B2 (ja) 抗イヌIgEモノクローナル抗体並びに抗イヌIgEモノクローナル抗体の重鎖可変領域及び軽鎖可変領域
CN102617734B (zh) 抗FGF-2抗体Dab-2及其应用
CN118496349A (zh) 抗猴痘病毒a35r蛋白的单克隆抗体2d7或其抗体片段
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
CN105906716B (zh) 埃可病毒9型vp1蛋白特异性抗原表位及其融合蛋白的制备、应用